Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$20,301 Mln
P/E Ratio
--
P/B Ratio
16.98
Industry P/E
--
Debt to Equity
0.16
ROE
-0.19 %
ROCE
-14.71 %
Div. Yield
0 %
Book Value
9.56
EPS
-1.52
CFO
$-1,528.27 Mln
EBITDA
$-2,147.13 Mln
Net Profit
$-2,244.55 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| -6.46 | -0.09 | -12.12 | 63.95 | 55.32 | 34.57 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Midcap 400
| -11.96 | -6.24 | -14.95 | -3.87 | 1.45 | 12.76 | 5.99 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| 150.81 | 55.94 | -56.99 | -6.16 | 195.40 | 141.33 | 54.91 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 67.29 | 84,945.55 | 18.39 | 6.07 | |
| 335.01 | 82,480.47 | 15.22 | -269.41 | |
| 217.12 | 18,166.13 | 24.56 | 9.37 | |
| 163.80 | 18,178.20 | 21.33 | 13.31 |
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier... screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. Address: 13011 McCallen Pass, Austin, TX, United States, 78753 Read more
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Natera Inc (NTRA) stood at $ 1,661 Mln as on 31-Dec-24
The share price of Natera Inc (NTRA) is $148.08 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Natera Inc (NTRA) has given a return of 55.32% in the last 3 years.
Natera Inc (NTRA) has a market capitalisation of $ 20,301 Mln as on 17-Apr-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Natera Inc (NTRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Natera Inc (NTRA) and enter the required number of quantities and click on buy to purchase the shares of Natera Inc (NTRA).
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. Address: 13011 McCallen Pass, Austin, TX, United States, 78753
The CEO & director of Dr. Matthew Rabinowitz Ph.D.. is Natera Inc (NTRA), and CFO & Sr. VP is Dr. Matthew Rabinowitz Ph.D..
There is no promoter pledging in Natera Inc (NTRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,845
|
|
|
1,825
|
|
|
8,654
|
|
|
8,149
|
| Natera Inc. (NTRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-19.42
|
|
Operating margin(%)
|
-10.55
|
|
Net Margin(%)
|
-11.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Natera Inc (NTRA) was $-190 Mln.
$-2.09
(
